Filter Results:
(5)
Show Results For
- All HBS Web
(5)
- Research (5)
- Faculty Publications (3)
Show Results For
- All HBS Web
(5)
- Research (5)
- Faculty Publications (3)
Page 1 of 5
Results
- March 2015 (Revised February 2022)
- Supplement
CV Ingenuity (B): Epilogue
By: Regina E. Herzlinger and Andrew Otazo
Duke Rohlen used a lea-nfunding, iconoclastic strategy for his start up for a drug eluding balloon for peripheral artery disease. His giant competitors were first movers. Did Duke obtain the funding he sought? How did his DEB fare versus that of his competitors?
The... View Details
Keywords: CV Ingenuity; CVI; Drug Eluting Balloon; DEB; Drug Eluting Stent; Angioplasty Balloon; FoxHollow; Medical Device; Medical Device Startup; Premarket Approval; PMA; Lutonix; Stellarex; LEVANT; ILLUMENATE; Clinical Trials; Peripheral Arterial Disease; PAD; Healthcare Startups; Covidien; Health Care and Treatment; Health Testing and Trials; Business Startups; Commercialization; Strategy; Health Industry; Medical Devices and Supplies Industry; United States; Europe
Herzlinger, Regina E., and Andrew Otazo. "CV Ingenuity (B): Epilogue." Harvard Business School Supplement 315-087, March 2015. (Revised February 2022.)
- April 2017
- Teaching Note
CV Ingenuity (A) and (B)
Teaching Note for HBS Nos. 315-045 and 315-087. View Details
- March 2015 (Revised January 2024)
- Case
CV Ingenuity (A): How to Evaluate the Commercial Viability of New Health Care Technologies
By: Regina E. Herzlinger and Andrew Otazo
Duke Rohlen (HBS MBA ’01) hoped to win over a prominent venture capital investor for Series B financing of his firm CVI that was creating a drug-eluting balloon (DES) to treat peripheral arterial disease. As a second-mover, Duke felt he was more likely to acquire... View Details
Keywords: CV Ingenuity; CVI; Drug Eluting Balloon; DEB; Drug Eluting Stent; Angioplasty Balloon; FoxHollow; Medical Device; Medical Device Startup; Premarket Approval; PMA; Lutonix; Stellarex; LEVANT; ILLUMENATE; Clinical Trials; Peripheral Arterial Disease; PAD; Healthcare Startups; Covidien; Health Care and Treatment; Health Testing and Trials; Business Startups; Commercialization; Health Industry; Medical Devices and Supplies Industry; United States; Europe
Herzlinger, Regina E., and Andrew Otazo. "CV Ingenuity (A): How to Evaluate the Commercial Viability of New Health Care Technologies." Harvard Business School Case 315-045, March 2015. (Revised January 2024.)
- 10 Jan 2017
- First Look
First Look at New Research: January 10, 2017
medical community. The case explores the challenges Ochsner faces in scaling and disseminating the program to other healthcare providers. Purchase this case: https://cb.hbsp.harvard.edu/cbmp/product/817028-PDF-ENG Harvard Business School Case 315-087 View Details
Keywords: Sean Silverthorne
- 01 Nov 2016
- First Look
First Look - November 1, 2016
(B): Vitalia Brasil This case should be distributed only after "Vitalia Franchise" (HBS Case No. 311-035) is distributed and discussed. Purchase this case: https://cb.hbsp.harvard.edu/cbmp/product/317022-PDF-ENG Harvard Business School Case 315-045 View Details
Keywords: Sean Silverthorne